Correct Answer: C. Para Tertiary butylphenol (PTBP)
Bindi leukoderma is a distinctive form of contact leukoderma caused by Para Tertiary Butylphenol (PTBP), a chemical used in the adhesive of bindis (decorative forehead marks worn in Indian culture). PTBP is a phenolic compound that acts as a hapten, binding to skin proteins and triggering a delayed-type hypersensitivity reaction (Type IV). The mechanism involves sensitization followed by depigmentation through oxidative stress and melanocyte destruction. When the bindi is worn repeatedly over the same area, PTBP penetrates the stratum corneum and causes localized depigmentation, resulting in a characteristic circular or oval hypopigmented patch on the forehead. This is particularly common in Indian women who wear bindis regularly. The depigmentation is often permanent or very slow to resolve even after discontinuation of bindi use. Unlike vitiligo (which is autoimmune), bindi leukoderma is a direct chemical-induced depigmentation. The diagnosis is clinical, supported by patch testing with PTBP, which typically shows a positive reaction in affected individuals. Management involves cessation of bindi use and counseling about alternative adhesive-free options.
Why the other options are wrong
A. p-phenylenediamine (PPD) — PPD is a chemical used in hair dyes and is a well-known contact allergen causing allergic contact dermatitis, not leukoderma. While PPD can cause severe reactions including erythema and edema, it does not characteristically cause depigmentation. This is an NBE trap pairing a common allergen with a depigmentation disorder. B. Crocein Scarlet MOO and Solvent Yellow 3 — These are azo dyes used in textile and cosmetic industries. They can cause contact dermatitis but are not associated with leukoderma or depigmentation. This option tests whether students confuse general chemical allergens with those specifically causing depigmentation. D. A Mono-benzyl ether of Hydroquinone (MBH) — MBH is a depigmenting agent used therapeutically in hyperpigmentation disorders, not a cause of contact leukoderma. While hydroquinone derivatives can cause depigmentation, MBH is intentionally used for this purpose and is not an occupational or cosmetic allergen causing unwanted leukoderma like PTBP.
High-Yield Facts
- Bindi leukoderma is caused by PTBP in bindi adhesives, presenting as localized depigmentation on the forehead in Indian women.
- PTBP acts as a hapten triggering Type IV delayed hypersensitivity and oxidative melanocyte destruction, distinct from autoimmune vitiligo.
- Patch testing with PTBP shows positive reaction in sensitized individuals and confirms the diagnosis of bindi leukoderma.
- Depigmentation in bindi leukoderma is often permanent or very slow to resolve, requiring cessation of bindi use and counseling on adhesive-free alternatives.
- Contact leukoderma from chemicals (PTBP, MBH, hydroquinone) differs from vitiligo by being localized, dose-dependent, and reversible if caught early.
Mnemonics
PTBP = Phenolic Tertiary Bindi Problem PTBP is the Phenolic compound in bindi adhesive causing leukoderma. Remember: Phenolic + Tertiary + Bindi = PTBP. Use this when you see 'bindi' in the question stem. Contact Leukoderma Chemicals (CLCs) PTBP (bindi), MBH (therapeutic depigmenter), Hydroquinone (skin bleach) — all cause depigmentation but PTBP is the occupational/cosmetic culprit in Indian practice. PTBP = unintended leukoderma; MBH = intended depigmentation.
NBE Trap
NBE pairs common contact allergens (PPD, azo dyes) with leukoderma to test whether students confuse general allergic contact dermatitis with specific depigmenting chemicals. The key discriminator is that bindi leukoderma is specifically a depigmentation disorder, not just dermatitis.
Clinical Pearl
In Indian clinical practice, bindi leukoderma is a culturally specific occupational dermatosis. A woman presenting with a well-demarcated circular hypopigmented patch on the forehead should prompt immediate inquiry about bindi use and adhesive type. Early recognition and cessation of PTBP-containing bindis can prevent permanent depigmentation, making this a teachable moment for patient counseling on safer cosmetic alternatives.
_Reference: Robbins & Cotran Pathological Basis of Disease (Ch. 25 - Skin); Harrison's Principles of Internal Medicine (Ch. 76 - Dermatologic Manifestations); Indian Dermatology textbooks (Valia & Valia on Contact Dermatitis and Occupational Dermatology)_